Inside Regeneron's R&D war room, sleepless nights and 'esprit de corps' in hunt for COVID-19 therapy

After two weeks of sleepless nights, growing comfort with conference calls and "esprit de corps," Regeneron researchers are making headway toward a COVID-19 therapy with the backing of international regulators and a "shared sense of urgency," said David Weinreich, Regeneron's head of global clinical development, on Friday.